Biomea Fusion prices $25 million public offering of shares and warrants

SAN CARLOS, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical-stage diabetes and obesity company with a strong balance sheet showing more cash than debt, announced Tuesday the pricing of its previously announced underwritten public offering expected to generate approximately $25 million in gross proceeds. According to InvestingPro analysis, the company maintains healthy liquidity with a current ratio of 3.68, though it’s currently burning through cash rapidly.

The offering consists of 11,195,121 shares of common stock with accompanying warrants, plus pre-funded warrants to purchase up to 1,000,000 shares with accompanying warrants for certain investors. Each share of common stock and accompanying warrant is priced at $2.05, while each pre-funded warrant and accompanying warrant is priced at $2.0499. The stock has shown remarkable momentum recently, with InvestingPro data showing a 32% return in the past week alone.

The accompanying warrants have an exercise price of $2.50 per share, are immediately exercisable, and will expire three years from issuance. Biomea has also granted underwriters a 30-day option to purchase up to an additional 1,829,268 shares and/or warrants.

Jefferies is acting as sole book-running manager for the offering, with H.C. Wainwright & Co. serving as lead manager. The offering is expected to close on October 8, 2025, subject to customary closing conditions.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the SEC on August 5, 2025 and declared effective on August 15, 2025.

Biomea Fusion is developing oral small molecule therapies, icovamenib and BMF-650, targeting metabolic disorders including diabetes and obesity. The company stated in its press release that proceeds from this offering will support its ongoing research and development activities. For deeper insights into BMEA’s financial health and growth prospects, investors can access comprehensive analysis and 15 additional ProTips through InvestingPro’s detailed research reports.

In other recent news, Biomea Fusion, Inc. has announced the commencement of an underwritten public offering of its common stock and accompanying warrants. The offering includes options for pre-funded warrants for certain investors, with Jefferies acting as the sole book-running manager. Additionally, Biomea Fusion has reported promising 52-week results from its Phase II COVALENT-111 clinical trial, which evaluates the experimental diabetes drug icovamenib. The trial demonstrated sustained treatment benefits for type 2 diabetes patients, with significant reductions in HbA1c levels maintained through Week 52.

Furthermore, Jefferies has initiated coverage on Biomea Fusion with a Buy rating, citing the potential of its oral small molecule medicines for diabetes and obesity treatments. The firm set a price target of $5.00, highlighting the company’s focus on innovative treatment options. These developments reflect Biomea Fusion’s ongoing efforts in advancing its clinical programs and securing financial resources to support its research initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.